Filing Flows › Indivior Pharmaceuticals (INDV) › Q2 2026
Indivior Pharmaceuticals (INDV) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 3, 2026
Indivior Pharmaceuticals (INDV) reported revenue of $343M for the second quarter 2026 (Q2 2026), +14% from a year earlier and +8% from the quarter before. Operating margin was 46.6%, net earnings $122M (35.6% of revenue).
Indivior Pharmaceuticals, Q2 2026: revenue $343M (+14% year over year), operating margin 46.6%, net earnings $122M, operating cash flow $229M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $343M | +8% | +14% |
| Gross profit | $294M | +6% | +18% |
| Operating profit | $160M | +17% | +122% |
| Net earnings | $122M | +37% | +578% |
| Operating cash flow | $229M | — | +45% |
| Free cash flow | $222M | — | +57% |
What changed
Revenue was $343.0M in Q2 2026, up 14% year over year and up 8% from the previous quarter.
Gross margin was 85.7%, up 2.9 points from Q2 2025. Operating profit was $160.0M, a 46.6% margin (up 22.8 points year over year). Of the extra revenue versus Q2 2025, 215% reached operating profit, above the 24% margin then. Operating expenses fell 25% while revenue rose 14%. Net earnings were $122.0M, up 578% year over year. The effective tax rate was 23.8%.
Operating cash flow was $229.0M (up 45% year over year), 188% of net earnings. Non-cash charges added back $2.0M of depreciation and amortization and $11.0M of share-based compensation. Working capital and other items added $94.0M. Capital expenditures of $7.0M left free cash flow of $222.0M.
Questions
What was Indivior Pharmaceuticals' revenue in the second quarter 2026?
Indivior Pharmaceuticals (INDV) reported revenue of $343M for the second quarter 2026 (Q2 2026), +14% from a year earlier and +8% from the quarter before.
Was Indivior Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $160M (46.6% of revenue) and net earnings $122M.